Successful trial shows tablet lowers risk of disease returning for kidney cancer patients
New trial launched to test cancer vaccine
A new vaccine aimed at enabling the immune system to fight against advanced cancer is being trialled in London and Guildford.
Scientists are testing the effectiveness and safety of the vaccine which works by resembling the natural immune responses generated by the body against bacterial and viral infections.
All patients with any solid tumour, irrespective of their type of cancer and tumour genetic profile, are believed to have the potential to benefit from this sort of treatment.
The (VAPER) trial is taking place at the National Institute for Health Research (NIHR) Guy’s and St Thomas' Clinical Research Facility and the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London (BRC). Other centres at the Surrey Cancer Research Institute (SCRI) at the University of Surrey and the Royal Surrey County Hospital are expected to commence patient recruitment later this year.
The first two patients have already been vaccinated in a trial that is anticipated to run for 18-24 months with recruitment of patients currently ongoing.
The aim of the trial is to establish the benefits of the vaccination programme, any side effects associated with it and the impact of this treatment on patients’ quality of life. Scientists hope the results will take them one step closer to developing an effective but nontoxic cancer therapy that can be used in clinical practice.
The clinical teams are being led by Dr James Spicer, Principal Investigator at the BRC and King's College London and Professor Hardev Pandha from SCRI.
Contact: Dr James Spicer